Gilead May Have Better Takeover Targets Than Tesaro
Executive Summary
Gilead has once more been mentioned as a prospective acquirer of Tesaro, but analysts at Datamonitor Healthcare's PharmaVitae believe that CAR-T and NASH are the areas where the company is more likely to seek buys that reduce its reliance on hepatitis C and HIV therapies.
You may also be interested in...
Sangamo Buys TxCell To Get In Early on CAR-Tregs In Immunology
Sangamo is to pay €72m to acquire France's TxCell, a specialist in chimeric antigen receptor-modified regulatory T-cells. It hopes ultimately to apply its zinc finger nuclease gene editing technology to develop next-generation allogeneic CAR-Treg therapies for immunological conditions.
Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships
Recent deal-making has seen new developments to further existing agreements, including Allergan licensing a depression candidate from the spinout of a company it bought in 2015. Also, updates on deals involving Celgene, AstraZeneca and Daiichi Sankyo.
QUADRA Supports Broader Use For Tesaro's PARP Inhibitor Zejula
Study in late-line use of heavily pretreated ovarian cancer may bring labeling closer in line with competitors, yet with limited commercial impact, analysts say.